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The potential utility of tumour-selective 5-fluorouracil treatment using attenuated Salmonella serovar typhimurium recombinant for
cytosine deaminase (TAPET-CD) has been documented in experimental settings. The present data demonstrate that in vivo
19F-
magnetic resonance spectroscopy measurements allow the outcome prediction of this prokaryotic-based therapy, demonstrating the
necessity of non-invasive real-time imaging techniques for treatment monitoring.
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Positron emission tomography and (nuclear) magnetic resonance
imaging (MRI) have been introduced to evaluate the biological
characteristics of tumours and to monitor the efficacy of treatment
on an individual basis. Fluor-containing chemotherapeutics, such
as 5-fluorouracil (5-FU) and its metabolites, can be detected non-
invasively in tumour and liver tissues using
19F-magnetic
resonance spectroscopy (
19F-MRS). Preclinical animal investiga-
tions and patient studies suggest that trapping of 5-FU in the
tumour correlates with response and may provide prognostic
information on treatment outcome (Wolf et al, 1990; Schlemmer
et al, 1999; Martino et al, 2005).
Ample data exist on the use of the cytosine deaminase (CD)
enzyme, which converts the nontoxic 5-fluorocytosine (5-FC) into
the cytostatic 5-FU, in a number of experimental settings. Among
these, we and others have demonstrated that recombinant bacteria
such as Clostridium and attenuated Salmonella, can be used to
transfer CD selectively to the rodent tumour microenvironment,
resulting in antitumour effects (Minton et al, 1995; Theys et al,
2001; King et al, 2002; Mei et al, 2002). In addition, we reported the
feasibility of
19F-MRS to assess non-invasively the intratumour
conversion of 5-FC into 5-FU mediated by CD-recombinant
Salmonella (Dresselaers et al, 2003).
The aim of the present study was to investigate the value of in vivo
19F-MRS to predict the success of the TAPET-CD/5-FC cancer therapy
system and to evaluate it as a tool to allow individualised treatment.
MATERIALS AND METHODS
HCT116 human colorectal carcinoma cells were xenografted
(1.5 10
6 cells per 100ml) subcutaneously at the lower flank of
8- to 10-week-old female NMRI nu/nu mice. Treatment and
19F-
MRS measurements started when tumour volumes reached
4300mm
3. Tumours were measured in three orthogonal dimen-
sions with a calliper and volumes were calculated according to the
formula ABC p/6.
TAPET-CD (VION Pharmaceuticals Inc., New Haven, CT, USA),
in detail described by Zheng et al (2000), was cultured as described
previously (Mei et al, 2002) and 2.0 10
6 bacteria were injected
intravenously (tail vein). Six days after TAPET-CD administration,
5-FC was daily administered intraperitoneally in one group of
animals (n¼12), whereas a control group (n¼4) received saline
according to the same schedule.
To determine the intratumour conversion activity of the
TAPET-CD, in vivo
19F-MRS experiments were performed in a
4.7T BIOSPEC horizontal magnet (Bruker), equipped with a
double-tuned (
19F-
1H) surface coil of 1cm diameter, as described
previously (Dresselaers et al, 2003).
19F-MRS measurements were
performed four times on each animal, starting 6 days after TAPET-
CD injection and then every sixth or seventh day. An additional
5-FC injection was given immediately before the
19F-MRS
measurements.
At the end of the follow-up period, animals were killed, tumours
excised and homogenates were made to quantify bacterial
colonisation, presence (Western blotting) and activity (thin-layer
chromatography (TLC)) of CD, according to Theys et al (2001).
Briefly, Western blotting was carried out by loading 25mgo f
tumour cell extracts on the gel. Anti-CD monoclonal antibody
(MTM Laboratories Inc., Westborough, MA, USA) in a 1:5000
dilution was used as primary antibody. After overnight incubation
of the sonicated lysates with 5-FC (10mgml
 1), the conversion
into 5-FU was analysed by TLC on silica gel plates eluted with
butanol. 5-Fluorocytosine and 5-FU were loaded as reference.
Histological evaluation of hypoxia and necrosis was performed on
paraffin-embedded tumour pieces after administration of the
exogenous hypoxia marker pimonidazole. Staining and evaluation
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Figure 1 (A) Growth delay for ‘responder’ (9/12; ’) and ‘nonresponder’ (3/12; K) animals. Sham saline-treated animals are indicated with m. Animals
in which a 5-FU signal could be detected using in vivo
19F-MRS during the follow-up period were marked as ‘responders’, the others as ‘nonresponders’. The
100% value represents the tumour volume at day 0 (ie volume at the start of 5-FC administration). Statistical significance at Po0.001 using linear regression
analysis is indicated (*). Data are shown as mean7s.e.m. (B) Representative spectra (13min/spectrum: TR¼0.75s; NA¼1024; LB¼6Hz; zerofilling to
4096 points) of a ‘nonresponder’ (top) and a ‘responder’ (bottom) animal. (C) Quantification of the amount of 5-FC and 5-FU using in vitro
19F-MRS on
perchloric acid tumour extracts of ‘responders’ (’) and ‘nonresponders’ (K). Statistical significance at Po0.05 using a nonparametric Mann–Whitney U
test is indicated (*). Data are shown as mean7s.e.m. (D–E) Western blotting and thin-layer chromatography (TLC) for CD expression and activity
respectively in tumour homogenates from HCT116 xenograft In NMRI nu/nu mice injected with TAPET-CD. TLC was done before (E left) and after
(E right) adding Luria–bertani medium to the tumour extracts with overnight incubation. ‘Responders’ are indicated with R, ‘nonresponders’ with NR. The þC
indicates a sample of bacterial lysate from in vitro growing TAPET-CD and represent the positive control.  C represents the negative control, that is,
bacterial lysate from the in vitro growing PC0698 strain, which does not encode CD.
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sof the sections were performed as described previously (Dubois
et al, 2004).
In vitro
19F-MRS analysis was performed on perchloric acid
extracts using a AMX360 (8.4T) spectrometer (Bruker, Karlsruhe,
Germany; Dresselaers et al, 2003).
All animal experiments were in agreement with national
guidelines, approved by the Animal Ethics Committee of
the University ‘KU Leuven’, Belgium, and procedures were
according to the guidelines defined by the UKCCCR (Workman
et al, 1998).
RESULTS
19F-MRS measurements were performed repeatedly on every
animal starting at 6 days after TAPET-CD administration and
immediately after the 5-FC injection. These spectroscopy analyses
allowed us to evaluate the in vivo intratumour conversion of 5-FC
into 5-FU, which resulted from TAPET-CD activity. Animals in
which a 5-FU signal could be detected during the follow-up period
were marked as ‘responders’ (9 out of 12), the others as ‘non-
responders’ (3 out of 12). Linear regression analysis showed a
significant tumour growth delay for the ‘responders’ compared to
the ‘non-responders’ (29.00 days; b¼5.72; Po0.001) and control
saline-treated group (29.83 days; b¼3.32; Po0.001), as witnessed
from the interaction between time and group (Figure 1A).
Representative spectra of ‘responder’ and ‘non-responder’ animals
are shown in Figure 1B. The final in vivo measurements were
subsequently confirmed by quantification of the 5-FU amount
using in vitro
19F-MRS analyses. Whereas equal amounts of 5-FC
were found, significant differences in 5-FU amount existed
between ‘responders’ and ‘non-responders’ (P¼0.044)
(Figure 1C). This was not caused by a different level of colonisation
because the number of viable bacteria present in the tumours was
not significantly different in both groups (equally high colonisa-
tion, 410
9cfug
 1 tumour tissue). In addition, Western blotting on
tumour extracts did not reveal differences in CD protein
expression (Figure 1D). To exclude presence of mutations within
the CD protein, lysates were made from bacteria isolated out of
tumours from both ‘responders’ and ‘non-responders’. TLC
experiments with these bacterial lysates demonstrated conversion
of 5-FC to 5-FU in all cases, indicating a fully functional CD
protein (data not shown). However, the ability for conversion of 5-
FC into 5-FU, as determined by TLC experiments on tumour
extracts, could only be shown in the ‘responders’ and not in the
‘non-responders’ group (Figure 1E left). This corresponds to the
very small amount of 5-FU detected in the ‘non-responder animals’
using the more sensitive in vitro
19F-MRS (Figure 1C). Interest-
ingly, the ‘no-conversion phenomenon’ in the ‘non-responder’
animals could be reversed by adding nutrients (Luria–Bertani
medium) to the tumour extracts and allowing the mixture incubate
overnight before making sonicated lysates (Figure 1E, right).
DISCUSSION
The present study shows that the dynamic 5-FC/5-FU conversion
in the human colorectal HCT116 tumour xenograft following
systemic injection of TAPET-CD and 5-FC can be monitored using
in vivo
19F-MRS. More importantly, we demonstrate the need for
sequential non-invasive
19F-MRS imaging as a tool for TAPET-CD/
5-FC therapy prediction. Given the fact that a pilot clinical trial
with TAPET-CD, in which two out of three refractory cancer
patients maintained stable disease when functional CD was
produced within the tumour (Nemunaitis et al, 2003) have already
started, our results point to the importance of not only monitoring
tumour colonisation but also CD functionality.
Tumours in which a 5-FU signal could be detected using in vivo
19F-MRS during the follow-up period were marked as ‘responders’,
the others were marked ‘non-responders’. Despite similar TAPET-
CD colonisation levels in all tumours, growth delay assays showed
a significant difference in success of the TAPET-CD/5-FC therapy
for the ‘responders’ vs ‘non-responders’ and the control saline-
treated animals. In vitro
19F-MRS analysis performed on the
perchloric acid extracts of the resected tumours taken at the end of
the follow-up period, confirmed the in vivo
19F-MRS 5-FC/5-FU
measurements. Intriguingly, Western blotting did not reveal a
difference in CD protein expression between the samples of
‘responders’ and ‘non-responders,’ and TLC analysis on bacterial
lysates confirmed the CD functionality in all cases. This indicates
that in the TAPET-CD present in the tumour, the CD gene was not
selectively lost. In other words, expression of CD by recombinant
bacteria in the tumour is not enough to establish an antitumour
effect when combined with 5-FC administration. Kamm et al
(1996) have argued that differences in 5-FU levels could be
explained by morphological heterogeneity in tumours. However,
we did not find histological differences in the amount of hypoxia/
necrosis between the tumours of ‘responders’ and ‘non-respon-
ders’ nor in the levels of 5-FC detected in the tumours via
19F-MRS
(both in vitro and in vivo). These results showed that prodrug
diffusion to the bacterial colonisation sites in both groups is not
impaired. As no differences were seen in bacterial colonisation and
CD protein expression, but significance was obtained in growth
delay between ‘responders’ and ‘non-responders’, we reasoned that
the observed difference was probably owing to either the presence
of an inhibitory factor in the tumours of the ‘non-responders’, or
to the lack of factors needed for CD enzyme activity. The catalytic
activity of CD is shown to be dependent on Fe
2þ or other divalent
metal ions that function as cofactor. Although it might be possible
that these cofactors are present in varying amounts among
tumours, this appeared not to be limiting in our study (data not
shown). Alternatively, low intratumoural pH or high endogenous
cytosine concentrations that compete with 5-FC for the active site
might reduce CD activity. However, as TLC experiments revealed
that adding fresh growth medium to the tumour extracts of non-
responders resulted in 5-FC/5-FU conversion, our data point
towards the absence of yet other necessary factors. From our
results, it is apparent that in a subgroup of tumours, the absence of
these necessary nutrients for efficient CD enzymatic activity can
result in a lack of antitumour efficacy. Therefore, our results stress
the importance of non-invasive real-time imaging tools as
19F-MRS
for individualised treatment as it allows the prediction of
antitumour efficacy when using TAPET-CD/5-FC therapy or
related treatments.
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